Tags

Type your tag names separated by a space and hit enter

Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
Am J Psychiatry. 2006 May; 163(5):833-8.AJ

Abstract

OBJECTIVE

Aripiprazole is a relatively new atypical antipsychotic agent that has been successfully employed in therapy for schizophrenia and schizoaffective disorders. A few neuroleptics have been used in therapy for patients with borderline personality disorder, which is associated with severe psychopathological symptoms. Aripiprazole, however, has not yet been tested for this disorder, and the goal of this study was to determine whether aripiprazole is effective in the treatment of several domains of symptoms of borderline personality disorder.

METHOD

Subjects meeting criteria for the Structured Clinical Interview for DSM-III-R Personality Disorders for borderline personality disorder (43 women and 9 men) were randomly assigned in a 1:1 ratio to 15 mg/day of aripiprazole (N=26) or placebo (N=26) for 8 weeks. Primary outcome measures were changes in scores on the symptom checklist (SCL-90-R), the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A), and the State-Trait Anger Expression Inventory and were assessed weekly. Side effects and self-injury were assessed with a nonvalidated questionnaire.

RESULTS

According to the intent-to-treat principle, significant changes in scores on most scales of the SCL-90-R, the HAM-D, the HAM-A, and all scales of the State-Trait Anger Expression Inventory were observed in the subjects treated with aripiprazole after 8 weeks. Self-injury occurred in the groups. The reported side effects were headache, insomnia, nausea, numbness, constipation, and anxiety.

CONCLUSIONS

Aripiprazole appears to be a safe and effective agent in the treatment of patients with borderline personality disorder.

Authors+Show Affiliations

Clinic for Psychosomatic Medicine, Inntalklinik, 84359 Simbach am Inn, Germany. m.nickel@inntalklinik.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16648324

Citation

Nickel, Marius K., et al. "Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: a Double-blind, Placebo-controlled Study." The American Journal of Psychiatry, vol. 163, no. 5, 2006, pp. 833-8.
Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163(5):833-8.
Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Pedrosa Gil, F., Bachler, E., Buschmann, W., Rother, N., Fartacek, R., Egger, C., Anvar, J., Rother, W. K., Loew, T. H., & Kaplan, P. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. The American Journal of Psychiatry, 163(5), 833-8.
Nickel MK, et al. Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: a Double-blind, Placebo-controlled Study. Am J Psychiatry. 2006;163(5):833-8. PubMed PMID: 16648324.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. AU - Nickel,Marius K, AU - Muehlbacher,Moritz, AU - Nickel,Cerstin, AU - Kettler,Christian, AU - Pedrosa Gil,Francisco, AU - Bachler,Egon, AU - Buschmann,Wiebke, AU - Rother,Nadine, AU - Fartacek,Reinhold, AU - Egger,Christoph, AU - Anvar,Javaid, AU - Rother,Wolfhardt K, AU - Loew,Thomas H, AU - Kaplan,Patrick, PY - 2006/5/2/pubmed PY - 2006/6/13/medline PY - 2006/5/2/entrez SP - 833 EP - 8 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 163 IS - 5 N2 - OBJECTIVE: Aripiprazole is a relatively new atypical antipsychotic agent that has been successfully employed in therapy for schizophrenia and schizoaffective disorders. A few neuroleptics have been used in therapy for patients with borderline personality disorder, which is associated with severe psychopathological symptoms. Aripiprazole, however, has not yet been tested for this disorder, and the goal of this study was to determine whether aripiprazole is effective in the treatment of several domains of symptoms of borderline personality disorder. METHOD: Subjects meeting criteria for the Structured Clinical Interview for DSM-III-R Personality Disorders for borderline personality disorder (43 women and 9 men) were randomly assigned in a 1:1 ratio to 15 mg/day of aripiprazole (N=26) or placebo (N=26) for 8 weeks. Primary outcome measures were changes in scores on the symptom checklist (SCL-90-R), the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A), and the State-Trait Anger Expression Inventory and were assessed weekly. Side effects and self-injury were assessed with a nonvalidated questionnaire. RESULTS: According to the intent-to-treat principle, significant changes in scores on most scales of the SCL-90-R, the HAM-D, the HAM-A, and all scales of the State-Trait Anger Expression Inventory were observed in the subjects treated with aripiprazole after 8 weeks. Self-injury occurred in the groups. The reported side effects were headache, insomnia, nausea, numbness, constipation, and anxiety. CONCLUSIONS: Aripiprazole appears to be a safe and effective agent in the treatment of patients with borderline personality disorder. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/16648324/Aripiprazole_in_the_treatment_of_patients_with_borderline_personality_disorder:_a_double_blind_placebo_controlled_study_ L2 - https://ajp.psychiatryonline.org/doi/10.1176/ajp.2006.163.5.833?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -